{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:42:54Z","timestamp":1792161774936,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ijrobp.2018.02.170","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T13:28:48Z","timestamp":1520515728000},"page":"1210-1218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study"],"prefix":"10.1016","volume":"102","author":[{"given":"Ismini C.","family":"Mainta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Tille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-6064","authenticated-orcid":false,"given":"Thomas","family":"De Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Vall\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Buchegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Miralbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2018.02.170_bib1","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1158\/1078-0432.CCR-11-2711","article-title":"Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer","volume":"18","author":"Milosevic","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib2","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1158\/0008-5472.CAN-07-0561","article-title":"Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response","volume":"67","author":"Milosevic","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib3","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00330-006-0431-y","article-title":"Imaging oxygenation of human tumours","volume":"17","author":"Padhani","year":"2007","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10555-008-9144-9","article-title":"Clinical biomarkers for hypoxia targeting","volume":"27","author":"Le","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib5","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1615\/CritRevOncog.v20.i5-6.130","article-title":"Hypoxia-induced signaling promotes prostate cancer progression: Exosomes role as messenger of hypoxic response in tumor microenvironment","volume":"20","author":"Deep","year":"2015","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1677\/erc.1.00728","article-title":"Hypoxia-inducible factor-1 in human breast and prostate cancer","volume":"13","author":"Kimbro","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.molonc.2008.03.006","article-title":"Molecular aspects of tumour hypoxia","volume":"2","author":"Rademakers","year":"2008","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib8","doi-asserted-by":"crossref","first-page":"16802","DOI":"10.1038\/srep16802","article-title":"The accumulation mechanism of the hypoxia imaging probe \u201cFMISO\u201d by imaging mass spectrometry: Possible involvement of low-molecular metabolites","volume":"5","author":"Masaki","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/j.semnuclmed.2014.10.006","article-title":"F-18 fluoromisonidazole for imaging tumor hypoxia: Imaging the microenvironment for personalized cancer therapy","volume":"45","author":"Rajendran","year":"2015","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijrobp.2014.09.045","article-title":"A comparative study of the hypoxia PET tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a preclinical tumor model","volume":"91","author":"Peeters","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib11","first-page":"365","article-title":"PET radiopharmaceuticals for imaging of tumor hypoxia: A review of the evidence","volume":"4","author":"Lopci","year":"2014","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3413\/nukmed-00328-10-07","article-title":"Two or four hour [18F]FMISO-PET in HNSCC. When is the contrast best?","volume":"50","author":"Abolmaali","year":"2011","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib13","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0360-3016(96)00325-2","article-title":"Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients","volume":"36","author":"Rasey","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib14","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1007\/s00259-014-2786-7","article-title":"Potential of hybrid 18F-fluorocholine PET\/MRI for prostate cancer imaging","volume":"41","author":"de Perrot","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1259\/bjr\/18700614","article-title":"Dose escalation to combat hypoxia in prostate cancer: A radiobiological study on clinical data","volume":"79","author":"Wang","year":"2006","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib16","first-page":"1014","article-title":"Hypoxia image guided radiotherapy: Current status; clinical biomarkers of hypoxia targeting","volume":"3","author":"Yuan","year":"2016","journal-title":"Austin J Nucl Med Radiother"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.radonc.2013.04.027","article-title":"Boosting imaging defined dominant prostatic tumors: A systematic review","volume":"107","author":"Bauman","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1748-717X-7-66","article-title":"The prognostic value of expression of HIF1\u03b1, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy","volume":"7","author":"Weber","year":"2012","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","article-title":"Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study","volume":"9","author":"Vergis","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib20","first-page":"5830","article-title":"Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases","volume":"59","author":"Zhong","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijrobp.2006.08.077","article-title":"Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome","volume":"67","author":"Green","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib22","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.1158\/1078-0432.CCR-07-1257","article-title":"Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer","volume":"13","author":"Schlomm","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib23","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0360-3016(03)01621-3","article-title":"Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer","volume":"58","author":"Parker","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib24","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/1097-0142(20001101)89:9<2018::AID-CNCR19>3.3.CO;2-P","article-title":"Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: An Eppendorf pO(2) study","volume":"89","author":"Movsas","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib25","first-page":"348","article-title":"Measurement of hypoxia-related parameters in three sublines of a rat prostate carcinoma using dynamic (18)F-FMISO-PET-CT and quantitative histology","volume":"5","author":"Mena-Romano","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib26","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1007\/s00259-011-1876-z","article-title":"Investigation on tumor hypoxia in resectable primary prostate cancer as demonstrated by 18F-FAZA PET\/CT utilizing multimodality fusion techniques","volume":"38","author":"Garcia-Parra","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0969-8051(02)00442-0","article-title":"[18F]fluoroazomycinarabinofuranoside (18FAZA) and [18F]fluoromisonidazole (18FMISO): A comparative study of their selective uptake in hypoxic cells and PET\u00a0imaging in experimental rat tumors","volume":"30","author":"Sorger","year":"2003","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib28","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3109\/0284186X.2015.1067721","article-title":"Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia\u2014A simulation study","volume":"54","author":"Wack","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijrobp.2005.11.044","article-title":"An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance","volume":"65","author":"Carnell","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ijrobp.2007.01.018","article-title":"Hypoxia in prostate cancer:\u00a0Correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations","volume":"68","author":"Hoskin","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib31","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/0284186X.2016.1219046","article-title":"Analysis of relation between hypoxia PET imaging and tissue-based biomarkers during head and neck radiochemotherapy","volume":"55","author":"Bittner","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2967\/jnumed.112.111963","article-title":"18F-fluoromisonidazole PET\/CT: A potential tool for predicting primary endocrine therapy resistance in breast cancer","volume":"54","author":"Cheng","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib33","doi-asserted-by":"crossref","first-page":"7220","DOI":"10.1158\/1078-0432.CCR-05-0869","article-title":"Carbonic anhydrase IX expression and tumor oxygenation status do not correlate at the microregional level in locally advanced cancers of the uterine cervix","volume":"11","author":"Mayer","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib34","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1158\/1078-0432.CCR-04-2344","article-title":"Microregional expression of glucose transporter-1 and oxygenation status: Lack of correlation in locally advanced cervical cancers","volume":"11","author":"Mayer","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib35","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1158\/0008-5472.CAN-03-3566","article-title":"Lack of correlation between expression of HIF-1alpha protein and oxygenation status in identical tissue areas of squamous cell carcinomas of the uterine cervix","volume":"64","author":"Mayer","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0360-3016(03)00534-0","article-title":"Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha\/beta ratio","volume":"57","author":"Nahum","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib37","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/j.ijrobp.2011.05.037","article-title":"Hypoxic prostate\/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: Long-term results","volume":"82","author":"Turaka","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib38","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ijrobp.2011.11.017","volume":"82","author":"Dal Pra","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib39","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2011.10.038","article-title":"Castration therapy of prostate cancer results in downregulation of HIF-1\u03b1 levels","volume":"82","author":"Al-Ubaidi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib40","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/pros.22803","article-title":"Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate","volume":"74","author":"Regter","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/mrm.23062","article-title":"DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study","volume":"67","author":"Barrett","year":"2012","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib42","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00330-015-3688-1","article-title":"Prostate cancer: Assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI","volume":"25","author":"H\u00f6tker","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijrobp.2010.02.060","article-title":"Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: An in\u00a0vivo human study using susceptibility and relaxivity dynamic MRI","volume":"80","author":"Alonzi","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib45","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-4614-4989-8_42","article-title":"Blood flow and oxygenation status of prostate cancers","volume":"765","author":"Vaupel","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib46","first-page":"1851","article-title":"Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O","volume":"45","author":"Bruehlmeier","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib47","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s00259-013-2581-x","article-title":"Diffusion and perfusion correlates of the 18F-MISO PET lesion in acute stroke: Pilot study","volume":"41","author":"Alawneh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2012.11.014","article-title":"Radiosensitization of prostate cancer cells by the dual PI3K\/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions","volume":"106","author":"Potiron","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib49","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2016.00024","article-title":"Mechanistic insights into molecular targeting and combined modality therapy for aggressive, localized prostate cancer","volume":"6","author":"Dal Pra","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/mrm.23014","article-title":"Dynamic contrast-enhanced-MRI of tumor hypoxia","volume":"67","author":"Egeland","year":"2012","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2008.07.039","article-title":"An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer","volume":"74","author":"Newbold","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2018.02.170_bib52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.semradonc.2014.02.002","article-title":"Magnetic resonance imaging of the tumor microenvironment in radiotherapy: Perfusion, hypoxia, and metabolism","volume":"24","author":"Matsuo","year":"2014","journal-title":"Semin Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618304760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301618304760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T12:40:53Z","timestamp":1544013653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301618304760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0360301618304760"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.02.170","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2018.02.170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}